연구성과로 돌아가기
JCR 2024 저널 목록 (907 / 2104)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Journal Name | Publisher | ISSN | eISSN | Edition | WoS Category | Total Citation | JIF | JIF Quartile | 상위 JCR(%) | JIF % | JIF Rank | 5-Year JIF | 5-Year Quartile | JIF w/o Self-Cites | Immediacy Index | JCI | JCI Rank | JCI Quartile | JCI Percentile | Eigenfactor Score | Normalized Eigenfactor | Article Influence Score | AIS Quartile | Citable Items | Articles in Citable Items (%) | Cited Half-Life | Citing Half-Life | Total Articles | Citable OA (%) | 수집시기 | 바로가기 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHINA OCEAN ENGINEERING | SPRINGER MEDIZIN VERLAG GmBH | 0890-5487 | 2191-8945 | SCIE | ENGINEERING, MECHANICAL | 1,596 | 2.2 | Q2 | 46.4 | 53.6 | 85/182 | 1.8 | Q3 | 2.1 | 1.0 | 0.47 | 103/184 | Q3 | 44.29 | 0.001 | 0.224 | 0.313 | Q3 | 85 | 98.8% | 5.8 | 8.2 | 84 | 50.8% | 2025-08-05 16:03:10 | 바로가기 |
| Clinical Cosmetic and Investigational Dermatology | DOVE MEDICAL PRESS LTD | 1178-7015 | 1178-7015 | SCIE | DERMATOLOGY | 4,390 | 2.2 | Q2 | 46.4 | 53.6 | 45/96 | 2.6 | Q2 | 2.1 | 0.4 | 0.81 | 38/96 | Q2 | 60.94 | 0.005 | 1.142 | 0.587 | Q2 | 300 | 86.0% | 4.0 | 6.4 | 258 | 99.7% | 2025-08-05 16:02:50 | 바로가기 |
| CLINICAL DRUG INVESTIGATION | ADIS INT LTD | 1173-2563 | 1179-1918 | SCIE | PHARMACOLOGY & PHARMACY | 2,979 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 2.5 | Q3 | 2.7 | 0.9 | 0.75 | 141/353 | Q2 | 60.20 | 0.003 | 0.639 | 0.718 | Q2 | 67 | 73.1% | 6.7 | 6.1 | 49 | 48.0% | 2025-08-05 16:04:34 | 바로가기 |
| Clinical Psychopharmacology and Neuroscience | KOREAN COLL NEUROPSYCHOPHARMACOLOGY | 1738-1088 | 2093-4327 | SCIE | PHARMACOLOGY & PHARMACY | 1,781 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 2.9 | Q2 | 2.3 | 0.6 | 0.65 | 180/353 | Q3 | 49.15 | 0.002 | 0.454 | 0.719 | Q2 | 73 | 90.4% | 4.9 | 9.8 | 66 | 99.1% | 2025-08-05 16:04:34 | 바로가기 |
| CLINICS IN DERMATOLOGY | ELSEVIER SCIENCE INC | 0738-081X | 1879-1131 | SCIE | DERMATOLOGY | 4,891 | 2.2 | Q2 | 46.4 | 53.6 | 45/96 | 2.5 | Q2 | 2.0 | 2.0 | 1.02 | 26/96 | Q2 | 73.44 | 0.002 | 0.497 | 0.629 | Q2 | 78 | 97.4% | 11.0 | 7.9 | 76 | 7.6% | 2025-08-05 16:02:50 | 바로가기 |
| DERMATOLOGIC SURGERY | LIPPINCOTT WILLIAMS & WILKINS | 1076-0512 | 1524-4725 | SCIE | DERMATOLOGY | 9,959 | 2.2 | Q2 | 46.4 | 53.6 | 45/96 | 2.7 | Q2 | 1.8 | 0.6 | 0.76 | 39/96 | Q2 | 59.90 | 0.005 | 1.099 | 0.687 | Q2 | 188 | 75.0% | 10.7 | 7.8 | 141 | 7.3% | 2025-08-05 16:02:50 | 바로가기 |
| Dermatologica Sinica | WOLTERS KLUWER MEDKNOW PUBLICATIONS | 1027-8117 | 2223-330X | SCIE | DERMATOLOGY | 425 | 2.2 | Q2 | 46.4 | 53.6 | 45/96 | 1.4 | Q3 | 1.6 | 0.8 | 0.60 | 53/96 | Q3 | 45.31 | 0.000 | 0.083 | 0.318 | Q3 | 24 | 83.3% | 5.2 | 6.2 | 20 | 83.3% | 2025-08-05 16:02:51 | 바로가기 |
| Discover Psychology | SPRINGERNATURE | N/A | 2731-4537 | ESCI | PSYCHOLOGY, MULTIDISCIPLINARY | 191 | 1.6 | Q2 | 46.4 | 53.6 | 103/221 | 1.7 | Q3 | 1.5 | 0.1 | 0.47 | 142/221 | Q3 | 35.97 | 0.000 | 0.071 | 0.410 | Q3 | 207 | 85.0% | 2.3 | 8.5 | 176 | 99.3% | 2025-08-05 16:36:14 | 바로가기 |
| Drug Testing and Analysis | WILEY | 1942-7603 | 1942-7611 | SCIE | PHARMACOLOGY & PHARMACY | 4,605 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 2.7 | Q3 | 2.0 | 0.8 | 0.76 | 134/353 | Q2 | 62.18 | 0.003 | 0.769 | 0.477 | Q3 | 176 | 94.3% | 5.2 | 7.2 | 166 | 37.9% | 2025-08-05 16:04:34 | 바로가기 |
| ECOLOGICAL ENGINEERING | ELSEVIER | 0925-8574 | 1872-6992 | SCIE | ENGINEERING, ENVIRONMENTAL | 21,565 | 4.1 | Q2 | 46.4 | 53.6 | 39/83 | 4.3 | Q2 | 3.8 | 0.7 | 0.77 | 29/83 | Q2 | 65.66 | 0.008 | 1.887 | 0.779 | Q2 | 222 | 95.5% | 8.5 | 8.3 | 212 | 25.2% | 2025-08-05 16:33:29 | 바로가기 |
| EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | SPRINGER HEIDELBERG | 0031-6970 | 1432-1041 | SCIE | PHARMACOLOGY & PHARMACY | 8,344 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 2.7 | Q3 | 2.6 | 1.0 | 0.60 | 204/353 | Q3 | 42.35 | 0.005 | 1.179 | 0.760 | Q2 | 163 | 67.5% | 10.3 | 7.2 | 110 | 31.2% | 2025-08-05 16:04:33 | 바로가기 |
| EXPERT OPINION ON EMERGING DRUGS | TAYLOR & FRANCIS LTD | 1472-8214 | 1744-7623 | SCIE | PHARMACOLOGY & PHARMACY | 897 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 2.7 | Q3 | 2.7 | 1.3 | 0.39 | 270/353 | Q4 | 23.65 | 0.001 | 0.214 | 0.850 | Q2 | 28 | 0.0% | 6.5 | 6.0 | 0 | 10.8% | 2025-08-05 16:04:35 | 바로가기 |
| EXPERT OPINION ON PHARMACOTHERAPY | TAYLOR & FRANCIS LTD | 1465-6566 | 1744-7666 | SCIE | PHARMACOLOGY & PHARMACY | 6,801 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 3.0 | Q2 | 2.6 | 0.8 | 0.49 | 237/353 | Q3 | 33.00 | 0.005 | 1.138 | 0.736 | Q2 | 199 | 17.6% | 7.6 | 5.7 | 35 | 13.1% | 2025-08-05 16:04:34 | 바로가기 |
| Food and Environmental Virology | SPRINGER | 1867-0334 | 1867-0342 | SCIE | VIROLOGY | 1,353 | 2.7 | Q2 | 46.4 | 53.6 | 20/42 | 3.1 | Q2 | 2.5 | 0.8 | 0.72 | 19/42 | Q2 | 55.95 | 0.001 | 0.205 | 0.559 | Q3 | 42 | 88.1% | 6.0 | 6.6 | 37 | 41.1% | 2025-08-05 16:05:32 | 바로가기 |
| Future Pharmacology | MDPI | N/A | 2673-9879 | ESCI | PHARMACOLOGY & PHARMACY | 315 | 2.7 | Q2 | 46.4 | 53.6 | 164/352 | 2.7 | Q3 | 2.7 | 0.8 | 0.46 | 251/353 | Q3 | 29.04 | 0.000 | 0.075 | 0.419 | Q3 | 48 | 43.8% | 1.9 | 6.6 | 21 | 100.0% | 2025-08-05 16:04:35 | 바로가기 |
페이지 이동: